1
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Gastroenterologist. 362:1907–1917.
2003.
|
2
|
Nguyen VTT, Law MG and Dore GJ: Hepatitis
B-related hepatocellular carcinoma: Epidemiological characteristics
and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hiotis SP, Rahbari NN, Villanueva GA,
Klegar E, Luan W, Wang Q and Yee HT: Hepatitis B vs. hepatitis C
infection on viral hepatitis-associated hepatocellular carcinoma.
BMC Gastroenterol. 12:642012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Waghray A, Murali AR and Menon KN:
Hepatocellular carcinoma: From diagnosis to treatment. World J
Hepatol. 7:1020–1029. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yuen MF, Hou JL and Chutaputti A; Asia
Pacific Working Party on Prevention of Hepatocellular Carcinoma, :
Hepatocellular carcinoma in the Asia pacific region. J
Gastroenterol Hepatol. 24:346–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Giannini EG, Farinati F, Ciccarese F,
Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E,
Zoli M, Borzio F, et al: Prognosis of untreated hepatocellular
carcinoma. Hepatology. 61:184–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Jemal A, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Beckedorff FC, Amaral MS,
Deocesano-Pereira C and Verjovski-Almeida S: Long non-coding RNAs
and their implications in cancer epigenetics. Biosci Rep.
33:e000612013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Jin Y, Wu D, Yang W, Weng M, Li Y, Wang X,
Zhang X, Jin X and Wang T: Hepatitis B virus × protein induces
epithelial-mesenchymal transition of hepatocellular carcinoma cells
by regulating long non-coding RNA. Virol J. 14:2382017. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lv D, Wang Y, Zhang Y, Cui P and Xu Y:
Downregulated long non-coding RNA DREH promotes cell proliferation
in hepatitis B virus-associated hepatocellular carcinoma. Oncol
Lett. 14:2025–2032. 2017. View Article : Google Scholar : PubMed/NCBI
|
12
|
Yu TT, Xu XM, Hu Y, Deng JJ, Ge W, Han NN
and Zhang MX: Long noncoding RNAs in hepatitis B
virus-relatedhepatocellular carcinoma. World J Gastroenterol.
21:7208–7217. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Deng X, Zhao XF, Liang XQ, Chen R, Pan YF
and Liang J: Linc00152 promotes cancer progression in hepatitis B
virus-associated hepatocellular carcinoma. Biomed Pharmacother.
90:100–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Li J, Wang X, Tang J, Jiang R, Zhang W, Ji
J and Sun B: HULC and Linc00152 act as novel biomarkers in
predicting diagnosis of hepatocellular carcinoma. Cell Physiol
Biochem. 37:687–696. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang K, Guo WX, Li N, Gao CF, Shi J, Tang
YF, Shen F, Wu MC, Liu SR and Cheng SQ: Serum LncRNAs profiles
serve as novel potential biomarkers for the diagnosis of
HBV-positive hepatocellular carcinoma. PLoS One. 10:e01449342015.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Lu J, Xie F, Geng L, Shen W, Sui C and
Yang J: Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935
expression profile in patients with hepatocellular carcinoma and
HBV. Tumor Biol. 36:3231–3236. 2015. View Article : Google Scholar
|
17
|
Nguyen QT, Lee EJ, Huang MG, Park YI,
Khullar A and Plodkowski RA: Diagnosis and treatment of patients
with thyroid cancer. Am Health Drug Benefits. 8:30–40.
2015.PubMed/NCBI
|
18
|
Servant N, Roméjon J, Gestraud P, La Rosa
P, Lucotte G, Lair S, Bernard V, Zeitouni B, Coffin F,
Jules-Clément G, et al: Bioinformatics for precision medicine in
oncology: Principles and application to the SHIVA clinical trial.
Front Genet. 5:1522014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wang Z, Wu Q, Feng S, Zhao Y and Tao C:
Identification of four prognostic LncRNAs for survival prediction
of patients with hepatocellular carcinoma. Peerj. 5:e35752017.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Zheng H, Li P, Kwok JG, Korrapati A, Li
WT, Qu Y, Wang XQ, Kisseleva T, Wang-Rodriguez J and Ongkeko WM:
Alcohol and hepatitis virus-dysregulated lncRNAs as potential
biomarkers for hepatocellular carcinoma. Oncotarget. 9:224–235.
2018. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yuan W, Sun Y, Liu L, Zhou B, Wang S and
Gu D: Circulating LncRNAs serve as diagnostic markers for
hepatocellular carcinoma. Cell Physiol Biochem. 44:125–132. 2017.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Melis M, Diaz G, Kleiner DE, Zamboni F,
Kabat J, Lai J, Mogavero G, Tice A, Engle RE, Becker S, et al:
Viral expression and molecular profiling in liver tissue versus
microdissected hepatocytes in hepatitis B virus-associated
hepatocellular carcinoma. J Transl Med. 12:2302014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Deng YB, Nagae G, Midorikawa Y, Yagi K,
Tsutsumi S, Yamamoto S, Hasegawa K, Kokudo N, Aburatani H and
Kaneda A: Identification of genes preferentially methylated in
hepatitis C virus-related hepatocellular carcinoma. Cancer Sci.
101:1501–1510. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Hoshida Y, Nijman SM, Kobayashi M, Chan
JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K,
Hashimoto M, et al: Integrative transcriptome analysis reveals
common molecular subclasses of human hepatocellular carcinoma.
Cancer Res. 69:7385–7392. 2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Shtraizent N, DeRossi C, Nayar S,
Sachidanandam R, Katz LS, Prince A, Koh AP, Vincek A, Hadas Y,
Hoshida Y, et al: MPI depletion enhances O-GlcNAcylation of p53 and
suppresses the Warburg effect. elife. 6:e224772017. View Article : Google Scholar : PubMed/NCBI
|
26
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
27
|
Irizarry RA, Bolstad BM, Collin F, Cope
LM, Hobbs B and Speed TP: Summaries of Affymetrix GeneChip probe
level data. Nucleic Acids Res. 31:e152003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Larkin MA, Blackshields G, Brown NP,
Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm
A, Lopez R, et al: Clustal W and Clustal X version 2.0.
Bioinformatics. 23:2947–2948. 2007. View Article : Google Scholar : PubMed/NCBI
|
29
|
Zhou M, Guo M, He D, Wang X, Cui Y, Yang
H, Hao D and Sun J: A potential signature of eight long non-coding
RNAs predicts survival in patients with non-small cell lung cancer.
J Transl Med. 13:2312015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhou M, Xu W, Yue X, Zhao H, Wang Z, Shi
H, Cheng L and Sun J: Relapse-related long non-coding RNA signature
to improve prognosis prediction of lung adenocarcinoma. Oncotarget.
7:29720–29738. 2016.PubMed/NCBI
|
31
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
32
|
Qi C, Hong L, Cheng Z and Yin Q:
Identification of metastasis-associated genes in colorectal cancer
using metaDE and survival analysis. Oncol Lett. 11:568–574. 2016.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Wang X, Kang DD, Shen K, Song C, Lu S,
Chang LC, Liao SG, Huo Z, Tang S, Ding Y, et al: An R package suite
for microarray meta-analysis in quality control, differentially
expressed gene analysis and pathway enrichment detection.
Bioinformatics. 28:2534–2536. 2012. View Article : Google Scholar : PubMed/NCBI
|
34
|
Wang P, Wang Y, Hang B, Zou X and Mao JH:
A novel gene expression-based prognostic scoring system to predict
survival in gastric cancer. Oncotarget. 7:55343–55351.
2016.PubMed/NCBI
|
35
|
Goeman JJ: L1 penalized estimation in the
Cox proportional hazards model. Biom J. 52:70–84. 2010.PubMed/NCBI
|
36
|
Knafl GJ, Dixon JK, O'Malley JP, Grey M,
Deatrick JA, Gallo A and Knafl KA: Scale development based on
likelihood cross-validation. Stat Methods Med Res. 21:599–619.
2012. View Article : Google Scholar : PubMed/NCBI
|
37
|
Tilford CA and Siemers NO: Gene set
enrichment analysis. Methods Mol Biol. 563:99–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Huang R, Wang X, Zhang W, Zhangyuan G, Jin
K, Yu W, Xie Y, Xu X, Wang H and Sun B: Down-regulation of LncRNA
DGCR5 correlates with poor prognosis in hepatocellular carcinoma.
Cell Physiol Biochem. 40:707–715. 2016. View Article : Google Scholar : PubMed/NCBI
|
39
|
Yu MW, Yang SY, Yang SY, Hsiao TJ, Chang
HC, Lin SM, Liaw YF, Chen PJ and Chen CJ: Role of
N-acetyltransferase polymorphisms in hepatitis B related
hepatocellular carcinoma: Impact of smoking on risk. Gut.
47:703–709. 2000. View Article : Google Scholar : PubMed/NCBI
|
40
|
Zhang J, Xu F and Ouyang C: Joint effect
of polymorphism in the N-acetyltransferase 2 gene and smoking on
hepatocellular carcinoma. Tumor Biol. 33:1059–1063. 2012.
View Article : Google Scholar
|
41
|
Zhang X, Liu J, Yan S, Huang K, Bai Y and
Zheng S: High expression of N-acetyltransferase 10: A novel
independent prognostic marker of worse outcome in patients with
hepatocellular carcinoma. Int J Clin Exp Pathol. 8:14765–14771.
2015.PubMed/NCBI
|
42
|
Li Q, Liu X, Jin K, Lu M, Zhang C, Du X
and Xing B: NAT10 is upregulated in hepatocellular carcinoma and
enhances mutant p53 activity. BMC Cancer. 17:6052017. View Article : Google Scholar : PubMed/NCBI
|
43
|
Liu YX, Zhang SF, Ying-Hua JI, Guo SJ,
Wang GF and Zhang GW: Whole-exome sequencing identifies mutated
PCK2 and HUWE1 associated with carcinoma cell proliferation in a
hepatocellular carcinoma patient. Oncol Lett. 4:847–851. 2012.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Liu YM, Ma JH, Zeng QL, Lv J, Xie XH, Pan
YJ and Yu ZJ: MiR-19a affects hepatocyte autophagy via regulating
lncRNA NBR2 and AMPK/PPARα in D-GalN/lipopolysaccharide--stimulated
hepatocytes. J Cell Biochem. 119:358–365. 2017. View Article : Google Scholar : PubMed/NCBI
|
45
|
Ali AM, Bajaj V, Gopinath KS and Kumar A:
Characterization of the human SLC22A18 gene promoter and its
regulation by the transcription factor Sp1. Gene. 429:37–43. 2009.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Martin-kleiner I, Radetić M, Grbeša I,
Parazajder D, Kovačić M, Radetić M and Trošelj KG: The analysis of
the SLC22A18 gene and its natural antisense transcripts in human
papillary thyroid tumors. Proceedings of the Congress of the
Croatian Society of Biochemistry and Molecular Biology with
international participation (HDBMB 2008). Croatian Society of
Biochemistry and Molecular Biology; Zagreb: 2008
|
47
|
Li S, Chen X, Liu X, Yu Y, Pan H, Haak R,
Schmidt J, Ziebolz D and Schmalz G: Complex integrated analysis of
lncRNAs-miRNAs-mRNAs in oral squamous cell carcinoma. Oral Oncol.
73:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
48
|
Sun M, Geng D, Li S, Chen Z and Zhao W:
LncRNA PART1 modulates toll-like receptor pathway to influence cell
proliferation and apoptosis in prostate cancer cells. Biol Chem.
399:387–395. 2018. View Article : Google Scholar : PubMed/NCBI
|
49
|
Su H, Sun T, Wang H, Shi G, Zhang H, Sun F
and Ye D: Decreased TCL6 expression is associated with poor
prognosis in patients with clear cell renal cell carcinoma.
Oncotarget. 8:5789–5799. 2017.PubMed/NCBI
|